+关注
浮浮又沉沉
暂无个人介绍
IP属地:四川
0
关注
1
粉丝
0
主题
0
勋章
主贴
热门
浮浮又沉沉
07-06
$中银香港(02388)$
摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。
浮浮又沉沉
07-05
$KEEP(03650)$
今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力
浮浮又沉沉
06-29
$乐普生物-B(02157)$
乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的
浮浮又沉沉
06-27
$协鑫科技(03800)$
中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。
浮浮又沉沉
06-18
$美光科技(MU)$
美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?
浮浮又沉沉
06-11
$苹果(AAPL)$
苹果这AI发布会有些不及预期啊,没啥有新意的东西
浮浮又沉沉
06-05
$小米集团-W(01810)$
争议还是很大啊,股价能涨起来不
浮浮又沉沉
05-28
$恒大汽车(00708)$
这股票还能炒起来...
浮浮又沉沉
05-25
$理想汽车(LI)$
终于止跌了,最近走势真有点惨,又一次干到20以下了
浮浮又沉沉
05-20
$阅文集团(00772)$
最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。
浮浮又沉沉
05-17
$乐普生物-B(02157)$
最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。
浮浮又沉沉
05-16
$道琼斯(.DJI)$
一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。
浮浮又沉沉
05-12
$诺瓦瓦克斯医药(NVAX)$
牛逼哇,美股这反馈真灵敏
浮浮又沉沉
05-12
$英伟达(NVDA)$
OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗
浮浮又沉沉
05-05
$诺和诺德(NVO)$
诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。
浮浮又沉沉
04-28
$施贵宝(BMY)$
4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。
浮浮又沉沉
04-26
$信达生物(01801)$
信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。
浮浮又沉沉
04-25
$施贵宝(BMY)$
百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元
浮浮又沉沉
04-25
由于糖尿病和肥胖药物的需求爆炸式增长,
$礼来(LLY)$
周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。
浮浮又沉沉
04-24
$百济神州(BGNE)$
五年来,百济神州的研发投入一直遥遥领先领先其他药企,2022年首次超过百亿人民币(110.34亿元)后,2023年再度增长至125.33亿元。
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4129117073683340,"uuid":"4129117073683340","gmtCreate":1666013983317,"gmtModify":1712762427295,"name":"浮浮又沉沉","pinyin":"ffyccfufuyouchenchen","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":26,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"四川","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":324480474693688,"gmtCreate":1720247988553,"gmtModify":1720247990537,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02388\">$中银香港(02388)$</a> 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","listText":"<a href=\"https://laohu8.com/S/02388\">$中银香港(02388)$</a> 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","text":"$中银香港(02388)$ 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324480474693688","isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":324181343121712,"gmtCreate":1720151778729,"gmtModify":1720155423314,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/03650\">$KEEP(03650)$</a> 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","listText":"<a href=\"https://laohu8.com/S/03650\">$KEEP(03650)$</a> 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","text":"$KEEP(03650)$ 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324181343121712","isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":322132588163168,"gmtCreate":1719654801787,"gmtModify":1719657433615,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$</a> 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","listText":"<a href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$</a> 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","text":"$乐普生物-B(02157)$ 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322132588163168","isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":321371018088544,"gmtCreate":1719490052012,"gmtModify":1719490054338,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/03800\">$协鑫科技(03800)$</a> 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","listText":"<a href=\"https://laohu8.com/S/03800\">$协鑫科技(03800)$</a> 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","text":"$协鑫科技(03800)$ 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/321371018088544","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":318203057123592,"gmtCreate":1718724845088,"gmtModify":1718772822813,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a>美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a>美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","text":"$美光科技(MU)$ 美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/318203057123592","isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":315617531883592,"gmtCreate":1718085891036,"gmtModify":1718085892414,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a>苹果这AI发布会有些不及预期啊,没啥有新意的东西","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a>苹果这AI发布会有些不及预期啊,没啥有新意的东西","text":"$苹果(AAPL)$ 苹果这AI发布会有些不及预期啊,没啥有新意的东西","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315617531883592","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":313563565154376,"gmtCreate":1717558398115,"gmtModify":1717558399412,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$ </a>争议还是很大啊,股价能涨起来不","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$ </a>争议还是很大啊,股价能涨起来不","text":"$小米集团-W(01810)$ 争议还是很大啊,股价能涨起来不","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/313563565154376","isVote":1,"tweetType":1,"viewCount":3664,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3507779075099026","authorId":"3507779075099026","name":"寓言家","avatar":"https://static.tigerbbs.com/bc143f3104a28d0cd68dfc64805ec5cf","crmLevel":5,"crmLevelSwitch":1},"content":"已经调整结束了,再横几天应该会反弹","text":"已经调整结束了,再横几天应该会反弹","html":"已经调整结束了,再横几天应该会反弹"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":310740045250632,"gmtCreate":1716891602803,"gmtModify":1716891604469,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$ </a>这股票还能炒起来...","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$ </a>这股票还能炒起来...","text":"$恒大汽车(00708)$ 这股票还能炒起来...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/310740045250632","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309419403649200,"gmtCreate":1716569590556,"gmtModify":1716569592058,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/LI\">$理想汽车(LI)$ </a>终于止跌了,最近走势真有点惨,又一次干到20以下了","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/LI\">$理想汽车(LI)$ </a>终于止跌了,最近走势真有点惨,又一次干到20以下了","text":"$理想汽车(LI)$ 终于止跌了,最近走势真有点惨,又一次干到20以下了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/309419403649200","isVote":1,"tweetType":1,"viewCount":1670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":307916076814336,"gmtCreate":1716196749754,"gmtModify":1716196751371,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00772\">$阅文集团(00772)$ </a>最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00772\">$阅文集团(00772)$ </a>最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","text":"$阅文集团(00772)$ 最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307916076814336","isVote":1,"tweetType":1,"viewCount":398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306780390162704,"gmtCreate":1715932128245,"gmtModify":1715932131212,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$ </a>最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$ </a>最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","text":"$乐普生物-B(02157)$ 最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306780390162704","isVote":1,"tweetType":1,"viewCount":409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306196467384408,"gmtCreate":1715789673289,"gmtModify":1715790650474,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$道琼斯(.DJI)$ </a>一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$道琼斯(.DJI)$ </a>一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","text":"$道琼斯(.DJI)$ 一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306196467384408","isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":304793217507512,"gmtCreate":1715446919338,"gmtModify":1715567727751,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ </a>牛逼哇,美股这反馈真灵敏","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ </a>牛逼哇,美股这反馈真灵敏","text":"$诺瓦瓦克斯医药(NVAX)$ 牛逼哇,美股这反馈真灵敏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/304793217507512","isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":304793103585360,"gmtCreate":1715446888831,"gmtModify":1715472767800,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","text":"$英伟达(NVDA)$ OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304793103585360","isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":302669415907632,"gmtCreate":1714900084714,"gmtModify":1714900111728,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a>诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a>诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","text":"$诺和诺德(NVO)$ 诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/302669415907632","isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3519254194891755","authorId":"3519254194891755","name":"T111240","avatar":"https://static.tigerbbs.com/8764b9ea7383786f04bfd5ee5a705732","crmLevel":4,"crmLevelSwitch":0},"content":"超预期跌,期权亏几十个点","text":"超预期跌,期权亏几十个点","html":"超预期跌,期权亏几十个点"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":300219663528160,"gmtCreate":1714315284204,"gmtModify":1714315286873,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","text":"$施贵宝(BMY)$ 4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300219663528160","isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299530898391344,"gmtCreate":1714147182985,"gmtModify":1714147184993,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01801\">$信达生物(01801)$ </a>信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01801\">$信达生物(01801)$ </a>信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","text":"$信达生物(01801)$ 信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299530898391344","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299075546873928,"gmtCreate":1714041695180,"gmtModify":1714041696935,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","text":"$施贵宝(BMY)$ 百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299075546873928","isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299074808455216,"gmtCreate":1714041595704,"gmtModify":1714288544796,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"由于糖尿病和肥胖药物的需求爆炸式增长,<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","listText":"由于糖尿病和肥胖药物的需求爆炸式增长,<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","text":"由于糖尿病和肥胖药物的需求爆炸式增长,$礼来(LLY)$ 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299074808455216","isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":298749919072560,"gmtCreate":1713945707907,"gmtModify":1713946923346,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BGNE\">$百济神州(BGNE)$ </a>五年来,百济神州的研发投入一直遥遥领先领先其他药企,2022年首次超过百亿人民币(110.34亿元)后,2023年再度增长至125.33亿元。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BGNE\">$百济神州(BGNE)$ </a>五年来,百济神州的研发投入一直遥遥领先领先其他药企,2022年首次超过百亿人民币(110.34亿元)后,2023年再度增长至125.33亿元。","text":"$百济神州(BGNE)$ 五年来,百济神州的研发投入一直遥遥领先领先其他药企,2022年首次超过百亿人民币(110.34亿元)后,2023年再度增长至125.33亿元。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298749919072560","isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":313563565154376,"gmtCreate":1717558398115,"gmtModify":1717558399412,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$ </a>争议还是很大啊,股价能涨起来不","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$ </a>争议还是很大啊,股价能涨起来不","text":"$小米集团-W(01810)$ 争议还是很大啊,股价能涨起来不","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/313563565154376","isVote":1,"tweetType":1,"viewCount":3664,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3507779075099026","authorId":"3507779075099026","name":"寓言家","avatar":"https://static.tigerbbs.com/bc143f3104a28d0cd68dfc64805ec5cf","crmLevel":5,"crmLevelSwitch":1},"content":"已经调整结束了,再横几天应该会反弹","text":"已经调整结束了,再横几天应该会反弹","html":"已经调整结束了,再横几天应该会反弹"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":304793217507512,"gmtCreate":1715446919338,"gmtModify":1715567727751,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ </a>牛逼哇,美股这反馈真灵敏","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ </a>牛逼哇,美股这反馈真灵敏","text":"$诺瓦瓦克斯医药(NVAX)$ 牛逼哇,美股这反馈真灵敏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/304793217507512","isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":293814179627176,"gmtCreate":1712762498775,"gmtModify":1712762503179,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"老美这通胀一直居高不下,感觉前三个季度降息不可能了,甚至今年可能都不会降息<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$ </a>","listText":"老美这通胀一直居高不下,感觉前三个季度降息不可能了,甚至今年可能都不会降息<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$ </a>","text":"老美这通胀一直居高不下,感觉前三个季度降息不可能了,甚至今年可能都不会降息$纳斯达克(.IXIC)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/293814179627176","isVote":1,"tweetType":1,"viewCount":1363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":302669415907632,"gmtCreate":1714900084714,"gmtModify":1714900111728,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a>诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$ </a>诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","text":"$诺和诺德(NVO)$ 诺和诺德公布了2024年第一季度业绩,总营收653.49亿丹麦克朗(1丹币=0.14531美元,约94.96亿美元),按固定汇率同比增长24%,主要是由糖尿病(+24%)和肥胖护理(+42%)业务拉动;营业利润318.46亿丹麦克朗(46.28亿美元),同比增长30%。 诺和诺德的王牌产品非司美格鲁肽莫属。2024Q1,司美格鲁肽注射用降糖药Ozempic销售额持续攀升至278.10亿丹麦克朗(40.41亿美元),增速43%;口服降糖产品Rybelsus销售额为50.13亿丹麦克朗(7.28亿美元),同比增长17%;减肥药Wegovy销售额翻倍增长达93.77亿丹麦克朗(13.63亿美元)。司美格鲁肽3款产品合计创收422亿丹麦克朗(61.32亿美元)。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/302669415907632","isVote":1,"tweetType":1,"viewCount":658,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3519254194891755","authorId":"3519254194891755","name":"T111240","avatar":"https://static.tigerbbs.com/8764b9ea7383786f04bfd5ee5a705732","crmLevel":4,"crmLevelSwitch":0},"content":"超预期跌,期权亏几十个点","text":"超预期跌,期权亏几十个点","html":"超预期跌,期权亏几十个点"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":310740045250632,"gmtCreate":1716891602803,"gmtModify":1716891604469,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$ </a>这股票还能炒起来...","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$ </a>这股票还能炒起来...","text":"$恒大汽车(00708)$ 这股票还能炒起来...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/310740045250632","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309419403649200,"gmtCreate":1716569590556,"gmtModify":1716569592058,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/LI\">$理想汽车(LI)$ </a>终于止跌了,最近走势真有点惨,又一次干到20以下了","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/LI\">$理想汽车(LI)$ </a>终于止跌了,最近走势真有点惨,又一次干到20以下了","text":"$理想汽车(LI)$ 终于止跌了,最近走势真有点惨,又一次干到20以下了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/309419403649200","isVote":1,"tweetType":1,"viewCount":1670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":324480474693688,"gmtCreate":1720247988553,"gmtModify":1720247990537,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02388\">$中银香港(02388)$</a> 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","listText":"<a href=\"https://laohu8.com/S/02388\">$中银香港(02388)$</a> 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","text":"$中银香港(02388)$ 摩通发表报告指,香港银行股第二季股价跑赢恒生指数,认为行业的尾部风险已经退减,支持股份均值回归,但并非估值重估。该行表示,有关内地商业房地产的尾部风险,其忧虑正在减退;另外个别银行的股东回报亦有正面惊喜。不过虽然本地银行股估值便宜,但基于拨备前经营利润增长,以及信贷成本因素,估计今年上半年业绩带来正面惊喜有限,预期本地银行股下半年表现将大致与恒生指数相若。摩通预期中银香港(2388.HK)及大新银行(2356.HK)上半年业绩将跑赢同业。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324480474693688","isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":324181343121712,"gmtCreate":1720151778729,"gmtModify":1720155423314,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/03650\">$KEEP(03650)$</a> 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","listText":"<a href=\"https://laohu8.com/S/03650\">$KEEP(03650)$</a> 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","text":"$KEEP(03650)$ 今年整体不景气,Keep 618交易额还是挺牛逼的,硬件产品这一块还是能挣钱的,现在健身的人大多都会在意自己的装备,希望后面继续发力","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324181343121712","isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":322132588163168,"gmtCreate":1719654801787,"gmtModify":1719657433615,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$</a> 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","listText":"<a href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$</a> 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","text":"$乐普生物-B(02157)$ 乐普生物的在研管线还是很多的,公司的ADC候选药物包括MRG003、MRG002、MRG001、MRG004A以及CMG901。 MRG003是一种新型ADC类药物,靶向肿瘤细胞表面的EGFR,通过其抗体部分将细胞毒小分子靶向递送至肿瘤细胞中,且 MRG003与肿瘤细胞表面的EGFR结合后可引发Fc片段介导的免疫学毒性作用(如抗体依赖的细胞介导的细胞毒性,ADCC)。随后ADC-EGFR靶标复合物发生内吞进入细胞内,在pE/溶酶体作用下释放细胞毒小分子MMAE, MMAE靶向并抑制细胞内微管蛋白的聚合,从而导致肿瘤细胞死亡。 MRG002是一个全新的HER2靶点ADC药物,与曲妥珠单抗相比,由于其抗体成分MAB802可促进岩藻糖基化,从而降低抗体Fc区的ADCC活性。MAB802通过缬氨酸-瓜氨酸(vc)蛋白酶可裂解连接物与一甲基澳瑞他汀E(MMAE,一种高效抗微管剂)的共价连接。临床前研究结果表明,与T-DM1相比,在体外和体内动物研究中,MRG002对HER2阳性胃癌活性均有所提高。在中国,MRG002已完成多个适应症的探索研究,其中MRG002针对HER2阳性/低表达的局部晚期或转移性胃癌/胃食管交界处癌的探索性II期临床研究正在开展。 公司自研的MRG001针对血液肿瘤,全球目前尚未有获批的CD20靶向ADC药物,国内进入临床阶段的CD20靶向ADC药物仅有乐普生物的MRG001和特瑞思的TRS005。 MRG004A是一个靶向人组织因子(TF)的ADC药物,通过GlycoConnect™定点偶联技术完成构建。在临床前研究中,与传统ADC技术相比,MRG004A显著改善了血液循环中的稳定性,并增强了药效和耐受性。 CMG901是康诺亚和乐普生物共同开发的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322132588163168","isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":321371018088544,"gmtCreate":1719490052012,"gmtModify":1719490054338,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/03800\">$协鑫科技(03800)$</a> 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","listText":"<a href=\"https://laohu8.com/S/03800\">$协鑫科技(03800)$</a> 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","text":"$协鑫科技(03800)$ 中国光伏行业协会知识产权专业委员会联合国家工业信息安全发展研究中心、工业和信息化部电子知识产权中心近日发布《光伏产业专利发展年度报告(2024)》。报告显示,截至2023年底,我国光伏行业知识产权蓬勃发展,知识产权管理、运用水平进一步提高,知识产权生态建设稳步向前,专利申请总量累计达到16.6万件,有效专利量达到7.3万件,双双位居全球首位。硅料、硅片、电池、组件、逆变器等关键环节专利申请量增长迅速,分别达到1.29万件、2.83万件、4.28万件、4.78万件、3.79万件,知识产权规模优势持续巩固。以TOPCon电池、BC电池、异质结电池等为代表的新型电池领域创新活跃,专利申请量分别达到0.61万件、0.24万件、0.27万件。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/321371018088544","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":318203057123592,"gmtCreate":1718724845088,"gmtModify":1718772822813,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a>美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/MU\">$美光科技(MU)$ </a>美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","text":"$美光科技(MU)$ 美银美林:将美光科技(MU.O)列入1号美股股票推荐名单。 美国券商还有1号股票推荐名单这种东西?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/318203057123592","isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":315617531883592,"gmtCreate":1718085891036,"gmtModify":1718085892414,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a>苹果这AI发布会有些不及预期啊,没啥有新意的东西","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a>苹果这AI发布会有些不及预期啊,没啥有新意的东西","text":"$苹果(AAPL)$ 苹果这AI发布会有些不及预期啊,没啥有新意的东西","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315617531883592","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":307916076814336,"gmtCreate":1716196749754,"gmtModify":1716196751371,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00772\">$阅文集团(00772)$ </a>最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/00772\">$阅文集团(00772)$ </a>最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","text":"$阅文集团(00772)$ 最近庆余年2真火啊,老婆疯狂给我安利,刚开始看也就那样,后面越来也好看了,还有和我一样没看过第一部的人吗,查了一下是阅文集团出品的,感觉能给阅文带来不少利润。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/307916076814336","isVote":1,"tweetType":1,"viewCount":398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306780390162704,"gmtCreate":1715932128245,"gmtModify":1715932131212,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$ </a>最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/02157\">$乐普生物-B(02157)$ </a>最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","text":"$乐普生物-B(02157)$ 最近整体市场行情开始回暖,慢慢的有公司也开始配售了,今天乐普生物公告配售,相比之前30个交易日折价2.88%,这个增发价格不算太便宜,毕竟这段时间公司股价从底部翻了一倍多上来,只能理解为,这些机构对后市还是非常看好的。 选择在ASCO大会前发也是一个不错的时间节点,说不定会到时候ASCO会有不错的数据催化,再加上近期的行情,股价应该不会承压太多。 后续MRG003三季度也要报产催化,004 ASCO口头汇报,机构和专业投资者应该有信心。还有就是CG0070临床疗效和安全性最好,更长期看,公司基本面肯定是OK的。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306780390162704","isVote":1,"tweetType":1,"viewCount":409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306196467384408,"gmtCreate":1715789673289,"gmtModify":1715790650474,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$道琼斯(.DJI)$ </a>一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$道琼斯(.DJI)$ </a>一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","text":"$道琼斯(.DJI)$ 一段时间以来,美联储政策制定者一直表示,他们关注的是通胀的“超级核心”指标——即不包括住房的服务业。这部分的4月份通胀环比上涨0.42%,为去年12月以来的最低水平。但近几个月的持续大幅上涨使得同比增幅仍在攀升,达到一年来最高的4.91%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306196467384408","isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":304793103585360,"gmtCreate":1715446888831,"gmtModify":1715472767800,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a>OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","text":"$英伟达(NVDA)$ OpenAI创始人Sam Altman下周一的OpenAI演示不涉及GPT-5和搜索引擎,又有新东西了吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304793103585360","isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":300219663528160,"gmtCreate":1714315284204,"gmtModify":1714315286873,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","text":"$施贵宝(BMY)$ 4月25日,百时美施贵宝宣布了一项15亿美元的成本削减计划,将关闭位于加州的一个细胞疗法研发基地。加州湾区红木城的工厂将被关闭,未被解雇的员工将被重新安置到布里斯班的另一个工厂,也在湾区。 在这一消息被披露之前,该公司已经在最新的Q1财报会议上宣布裁员约2200人,约占其全球员工总数的6%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/300219663528160","isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299530898391344,"gmtCreate":1714147182985,"gmtModify":1714147184993,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01801\">$信达生物(01801)$ </a>信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/01801\">$信达生物(01801)$ </a>信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","text":"$信达生物(01801)$ 信达生物IBI343拟纳入突破性治疗品种,针对适应症为至少接受过二种系统性治疗的Claudin(CLDN)18.2表达阳性的晚期胃/胃食管交界处腺癌。根据信达生物公开资料,IBI343是一款靶向Claudin18.2的抗体偶联药物(ADC)。目前该产品正在针对Claudin18.2阳性、HER2阴性胃癌开展3期临床研究。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299530898391344","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299075546873928,"gmtCreate":1714041695180,"gmtModify":1714041696935,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/BMY\">$施贵宝(BMY)$ </a>百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","text":"$施贵宝(BMY)$ 百时美施贵宝 (BMS) 的 CAR-T 疗法 Abecma (idecabtagene vicleucel) 刚刚获得关键扩大批准,就已与 Cellares 达成了一项生产协议,旨在加快 CAR-T 供应。 这个全球产能预留和供应协议的预付款和里程碑付款价值高达 3.8 亿美元","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299075546873928","isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":299074808455216,"gmtCreate":1714041595704,"gmtModify":1714288544796,"author":{"id":"4129117073683340","authorId":"4129117073683340","name":"浮浮又沉沉","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"由于糖尿病和肥胖药物的需求爆炸式增长,<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","listText":"由于糖尿病和肥胖药物的需求爆炸式增长,<a target=\"_blank\" href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","text":"由于糖尿病和肥胖药物的需求爆炸式增长,$礼来(LLY)$ 周一宣布,已达成最终协议,从 Nexus Pharmaceuticals 收购一家注射药品生产设施。 礼来公司表示,经 FDA 批准的位于威斯康星州普莱森特普雷里的工厂可能会于 2025 年底开始生产。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/299074808455216","isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}